Viridian Therapeutics Inc [VRDN] stock is trading at $13.89, up 7.26%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRDN shares have gain 12.74% over the last week, with a monthly amount glided 3.19%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Viridian Therapeutics Inc [NASDAQ: VRDN] stock has seen the most recent analyst activity on June 11, 2024, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $29. Previously, Goldman started tracking the stock with Buy rating on June 06, 2024, and set its price target to $23. On May 09, 2024, downgrade downgraded it’s rating to Neutral. B. Riley Securities downgraded its rating to a Neutral and decreased its price target to $20 on May 09, 2024. BTIG Research started tracking with a Buy rating for this stock on June 14, 2023, and assigned it a price target of $46. In a note dated May 30, 2023, RBC Capital Mkts initiated an Outperform rating and provided a target price of $44 on this stock.
Viridian Therapeutics Inc [VRDN] stock has fluctuated between $10.93 and $24.18 over the past year. Currently, Wall Street analysts expect the stock to reach $36.18 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $13.89 at the most recent close of the market. An investor can expect a potential return of 160.48% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
Viridian Therapeutics Inc [NASDAQ:VRDN] reported sales of 0.29M for the trailing twelve months, which represents a drop of -26.53%. Gross Profit Margin for this corporation currently stands at -4.08% with Operating Profit Margin at -825.95%, Pretax Profit Margin comes in at -757.38%, and Net Profit Margin reading is -757.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.54 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.27 points at the first support level, and at 12.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.39, and for the 2nd resistance point, it is at 14.90.
Ratios To Look Out For
For context, Viridian Therapeutics Inc’s Current Ratio is 23.99. On the other hand, the Quick Ratio is 23.99, and the Cash Ratio is 3.51. Considering the valuation of this stock, the price to sales ratio is 3056.76, the price to book ratio is 2.31.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Jan 22 ’24 when 0.48 million shares were purchased.
